Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

13 Feb 2023

News You Might Have Missed: Feb 13th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Law & Politics

10 Feb 2023

Virginia & Hawaii Move Psychedelic Decrim Bills Forward

Virginia & Hawaii have both moved Psychedelic Decrim and study bills forward...

By Microdose NewsDesk

Don’t Miss

6 Feb 2023

News You Might Have Missed: Feb 6th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

3 Feb 2023

Terran Biosciences Files Patent for Oral DMT and 5-MeO-DMT

Terran Biosciences announces publication of PCT patent applications covering orally active forms of DMT and 5-MeO-DMT and long-acting MDMA...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

2 Feb 2023

Irwin Naturals Secures $40 Million Financing

Irwin Naturals Secures $40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million...

By Microdose NewsDesk

Industry

2 Feb 2023

FDA Grants Pharmather Orphan Drug Designation for KETARX (Ketamine)

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome...

By Microdose NewsDesk

Industry

1 Feb 2023

Numinus Receives Approval for Clinical Trial using Psilocybe Cubensis Tea

Numinus Receives Clinical Trial Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea...

By Microdose NewsDesk

Industry

31 Jan 2023

Origin Signs Letter of Intent to Acquire Safe Supply Streaming

Origin Enters into Binding Letter of Intent with Safe Supply Streaming Co....

By Microdose NewsDesk

Law & Politics

31 Jan 2023

4 More States Propose Psychedelic Legalization and Research

2023 has started off as a good year for psychedelic decriminalization....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.